[
 {
  "title": "Continuous Glucose Monitors and Impact of Food",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin Sayer, CEO of Dexcom, discusses the remarkable benefits of a continuous glucose monitor for the diabetes population. Peter shares his own invaluable insights he’s learned from wearing a CGM including the impact of sleep and stress on glucose as well as the unmatched power of a CGM to drive behavioral change.",
  "content_length": 315,
  "content_tokens": 63,
  "embedding": []
 },
 {
  "title": "Future Advancements of CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin also reveals some of the exciting partnerships and future advancements of their products benefiting not only those with type 1 and 2 diabetes, but also for the growing community of people interested in optimizing health and wellness.",
  "content_length": 239,
  "content_tokens": 40,
  "embedding": []
 },
 {
  "title": "CGM technology and Dexcom's G6",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "How CGM technology works, and what makes Dexcom’s G6 the best model yet [15:15]",
  "content_length": 79,
  "content_tokens": 25,
  "embedding": []
 },
 {
  "title": "Challenges of getting CGM insured",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Challenges of working in the US healthcare system and getting CGM insured [21:45]",
  "content_length": 81,
  "content_tokens": 19,
  "embedding": []
 },
 {
  "title": "Developing a smaller, user-friendly, and less costly product",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Developing an even smaller, more user-friendly, and less costly product while maintaining performance and accuracy [33:15]",
  "content_length": 122,
  "content_tokens": 25,
  "embedding": []
 },
 {
  "title": "Accuracy of the G6 and benefits of CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The incredible accuracy of the G6, recommended over-the-counter glucose meters, and the unmatched power of CGM to drive behavioral change [48:15]",
  "content_length": 145,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "Software improvements for type 2 diabetics",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Software improvements for type 2 diabetics, and the remarkable benefits of real-time feedback for driving behavioral change [58:15]",
  "content_length": 131,
  "content_tokens": 27,
  "embedding": []
 },
 {
  "title": "Cost and prescription of CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The cost of CGM, why you need a prescription, and when might there be a OTC option? [1:12:00]",
  "content_length": 93,
  "content_tokens": 29,
  "embedding": []
 },
 {
  "title": "Future places for CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Future places for CGM: Hospitals, nutrition apps, general health and wellness, and more [1:27:15]",
  "content_length": 97,
  "content_tokens": 26,
  "embedding": []
 },
 {
  "title": "Continuous Glucose Monitor for Diabetes",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin Sayer, CEO of Dexcom, discusses the remarkable benefits of a continuous glucose monitor for the diabetes population. Peter shares his own invaluable insights he’s learned from wearing a CGM including the impact of sleep and stress on glucose as well as the unmatched power of a CGM to drive behavioral change. Kevin also reveals some of the exciting partnerships and future advancements of more",
  "content_length": 400,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Continuous Glucose Monitor (CGM) Technology",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin Sayer, CEO of Dexcom, discusses the remarkable benefits of a continuous glucose monitor for the diabetes population. Peter shares his own invaluable insights he’s learned from wearing a CGM including the impact of sleep and stress on glucose as well as the unmatched power of a CGM to drive behavioral change. Kevin also reveals some of the exciting partnerships and future advancements of their products benefiting not only those with type 1 and 2 diabetes, but also for the growing community of people interested in optimizing health and wellness.",
  "content_length": 555,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Challenges of CGM Technology",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Challenges of working in the US healthcare system and getting CGM insured. Developing an even smaller, more user-friendly, and less costly product while maintaining performance and accuracy. Dexcom vs. the competitors, the less invasive options, and the fundamental problems needing to be solved with CGM technologies. The cost of CGM, why you need a prescription, and when might there be a OTC option?",
  "content_length": 402,
  "content_tokens": 83,
  "embedding": []
 },
 {
  "title": "Benefits of CGM Technology",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The incredible accuracy of the G6, recommended over-the-counter glucose meters, and the unmatched power of CGM to drive behavioral change. Software improvements for type 2 diabetics, and the remarkable benefits of real-time feedback for driving behavioral change. Future places for CGM: Hospitals, nutrition apps, general health and wellness, and more.",
  "content_length": 352,
  "content_tokens": 72,
  "embedding": []
 },
 {
  "title": "How CGM technology works, and what makes Dexcom’s G6 the best model yet",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "CGM technology is designed to measure glucose only. A small thin wire (like a human hair) inserts into subcutaneous tissue. That wire and those membranes then generate electrochemical signal that goes up into a transmitter that sits on top of the sensor. And inside that transmitters is an algorithm that converts that electrochemical signal to a glucose value. The key is it’s an enzymatic reaction which means that it can be done without multiple washes. With the new Dexcom G6 model, the filament that sits inside the patient is half inch under the skin. The insertion technology of the sensor, it goes in with a needle and the needle comes out. The needle is in your skin less time that it takes a hummingbird to flap its wings a couple of times so a patient doesn’t feel it. And then the sensor rests in the subcutaneous tissue and you really don’t feel that sensor at all.",
  "content_length": 878,
  "content_tokens": 192,
  "embedding": []
 },
 {
  "title": "Challenges of working in the US healthcare system and getting CGM insured",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Between 20 and 30% of the 1.3-2 million type 1 diabetes patients and 1.5 million who intensively use insulin have a CGM. Dexcom’s main competitors are Abbot and Medtronic. In January of 2017, they approved the use of CGM for “intensive insulin using” type 2 diabetes patients. Insurance can be a hassle as it is a constant battle with between doctors and insurance companies to get the patients covered. This is frustrating because as Kevin says, “80% of the type 1 population should be using continuous glucose monitoring”.",
  "content_length": 524,
  "content_tokens": 121,
  "embedding": []
 },
 {
  "title": "CGM and Diabetes Management",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The CGM gives them alerts and alarms and also alarms others who give care to those patients meaning someone in another country could be alerted and can take action (like calling the patient and waking them up). Big savings on the long-term complications of diabetes by using CGM. Looking at A1C, studies show at least a half a point drop over the course of a twelve month period, compared to multiple finger sticks. A full point drop for the patient’s, if you just look at them independently on continuous glucose monitoring use for a six-month period that is sustained. And that drop in A1C leads to reduced costs in the healthcare system.",
  "content_length": 640,
  "content_tokens": 134,
  "embedding": []
 },
 {
  "title": "Medicare and CGM Devices",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Recently got Medicare approval for CGM devices. It happened rather quickly, to Kevin’s surprise. But took some extra time to get approval for the phone app use as well due to “health care industry hurdles”.",
  "content_length": 206,
  "content_tokens": 47,
  "embedding": []
 },
 {
  "title": "Challenges of Doing Business with the US Healthcare System",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Tough challenge for businesses like Dexcom, “because you don’t exactly know, from a long-term planning standpoint, exactly what changes are going to come about.” Benefit of a single-payer system (like Canada): the incentive is aligned between the payer, the patient, the provider, over a long term. There are many downsides as well to the single payer system, and it’s probably unlikely to ever be the implemented in the US. “We have a really complicated health care system. . .But look, there are some things that I think it does well. And I think one of the things it does well, is it seems to set up an economic engine that allows for an innovation, that I think is hard to do outside of the United States.”",
  "content_length": 710,
  "content_tokens": 168,
  "embedding": []
 },
 {
  "title": "Future of Dexcom Sensors",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Developing an even smaller, more user-friendly, and less costly product while maintaining performance and accuracy. Exciting partnership with Verily. Verily is Alphabet Inc.’s (Google) research organization devoted to the study of life sciences. Verily approached Dexcom about partnering: Dexcom to focus on performance and accuracy while Verily will focus on miniaturization and convenience and what consumers like. Mutually decided it was a great partnership. So now they are co-developing future Dexcom sensors (much of the electronic side, communication, Bluetooth, etc. have been driven by the Verily engineers). “We focus on performance, patient convenience, and usability, and then taking costs out.”",
  "content_length": 707,
  "content_tokens": 146,
  "embedding": []
 },
 {
  "title": "Framework and Priorities for Developing New Products",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Framework and priorities for developing new products: Performance.",
  "content_length": 66,
  "content_tokens": 11,
  "embedding": []
 },
 {
  "title": "Nutrition and Cost",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Trying to make it as economically viable for the most amount of people.",
  "content_length": 71,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Glucose Monitoring and Performance",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Top priority is performance/accuracy of the device. As far as just bringing the overall accuracy percentage down, there’s not a whole lot to gain. Where there is to gain on the performance side is pushing the bell curve in on the performance of the sensor to whereby every experience is the same ⇒ aka “eliminating the outliers”",
  "content_length": 328,
  "content_tokens": 74,
  "embedding": []
 },
 {
  "title": "Glucose Monitoring and Patient Experience",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Next priority is patient experience: Size, Ease of use, How often do you have to change out the sensor, Software.",
  "content_length": 113,
  "content_tokens": 26,
  "embedding": []
 },
 {
  "title": "Glucose Monitoring and Algorithms",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The next thing on the horizon for type one diabetes is to develop algorithms to go with the sensor. . . for automated insulin delivery. In time, the algorithms will be able to regulate your insulin delivery all throughout the day whether you’re high or you’re low and detect things like meals (he just ate food, lets delivery insulin now). Just acquired an existing algorithm that helps with insulin dosing during the night time. Decision support: “We also think we can take these algorithms and apply them to people who use multiple daily injections as well to develop decision support.”",
  "content_length": 588,
  "content_tokens": 120,
  "embedding": []
 },
 {
  "title": "CGM and A1C",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "CGM can reduce A1C (and incidences of hypoglycemia). Reduced A1C (even if only 8.0 to 7.8 that can make a big difference in long run). Reduction in incidences of “bad outcomes” like hypoglycemia and hyperglycemia.",
  "content_length": 213,
  "content_tokens": 64,
  "embedding": []
 },
 {
  "title": "CGM and Standard Deviation",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "CGM allows Peter to see his standard deviation of his glucose levels which is “another variable that I find very informative.”",
  "content_length": 126,
  "content_tokens": 27,
  "embedding": []
 },
 {
  "title": "CGM and Finger Sticking Tips",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter is stunned by how accurate the G6 is when he tests it against a finger stick blood meter. The reliable nature of the G6 allows for Peter to stop doing their finger sticks which can be incredibly painful. Tips for finger sticking and recommended over-the-counter blood glucose meter.",
  "content_length": 288,
  "content_tokens": 58,
  "embedding": []
 },
 {
  "title": "CGM as a Driver of Behavioral Change",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter believes that the use of a CGM, at the very least, is a powerful driver of behavioral change. It is really hard to not pay attention to how activities in your life, mostly food, but not just food, stress affects your glucose readings.",
  "content_length": 240,
  "content_tokens": 52,
  "embedding": []
 },
 {
  "title": "Stress and Glucose Levels",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter tells patients that fasting glucose is not nearly as helpful as people think it is inside of a reasonably physiologic range. Fasting glucose of 130, that’s a different situation, there’s something going on there. But a fasting glucose of 100 instead of being 90 can very easily be explained by cortisol or hepatic glucose output for some other reason that’s not a function of insulin resistance. It’s amazing what stress can do to your glucose level.",
  "content_length": 456,
  "content_tokens": 98,
  "embedding": []
 },
 {
  "title": "Junk Food Horror Stories",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter loves trail mix when at the airport (comfort food). His glucose will spike to 130+ after eating it. Kevin once at a huge cup of yogurt covered raisins and his glucose spiked over 200. His body “overshot” his insulin and dropped his glucose down to 70. The real problem in type 2 diabetes is that we have fixated so much on just the glucose and not worrying about how we get there.",
  "content_length": 386,
  "content_tokens": 88,
  "embedding": []
 },
 {
  "title": "Therapies that Save Lives with Type 2 Diabetes",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Metformin, where you’re actually fixing the glucose side of the equation and not just adding more insulin to the system. The SGLT2 inhibitors, these are the things that are getting the glucose out of the system.",
  "content_length": 211,
  "content_tokens": 48,
  "embedding": []
 },
 {
  "title": "Nutrition and Glucose Monitoring",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Is there any way it is algorithmically possible to estimate the average insulin that a non-diabetic would make over the course of the day based on glucose data points? We do believe that it’s possible to measure how quickly insulin reacts and how much by the slope of the glucose curves, but not at our five-minute measurement intervals. Dexcom is openly sharing information with other platforms to try to collaborate on these types of future developments.",
  "content_length": 456,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Real-time Feedback and Behavioral Change",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Real-time feedback as a driver of behavioral change. Peter is boycotting grapes after being shocked by his glucose reaction. Kevin hasn’t touched yogurt covered raisins since his experience. “I really think that CGM has the potential to change the way people eat more than any other technology I have ever laid eyes on.” says Peter. “I also believe in real-time feedback. I think it’s very difficult to curb a person’s behavior when the feedback loop is too long like the weight on the scale, or the blood test that you get at your doctor every six months.”",
  "content_length": 557,
  "content_tokens": 130,
  "embedding": []
 },
 {
  "title": "Software for Type 2 Diabetics",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Building software to help type 2 diabetics (and non-diabetics). An analysis at the end of the day where we complement somebody, “you kept your glucose within range extremely well“. Prompts from the monitor to help you do better ⇒ “What did you eat for dinner today?” Integrating the CGM data into a food database with photos (i.e. take a picture of the foods you eat). Then you can look back and say, “Well, I ate those scrambled eggs this morning, and my glucose values didn’t go up. Maybe scrambled eggs for breakfast is a good thing for me.” Then you take a picture of pancakes and the software recognizes them and you get reminded ⇒ “You know, you had pancakes a month ago, and that may not have been the outcome that you’re looking for.”",
  "content_length": 742,
  "content_tokens": 186,
  "embedding": []
 },
 {
  "title": "Exercise and Stress",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Exercise and stress: the effect of your psychological state. It’s not just what you eat, but it’s the physiologic state you are in when you eat it. It’s a very different glycemic response if you eat a bowl of pasta after you’ve exercised intensely for 30 minutes versus eating it after having not exercised. “It can’t be understated how much higher my glucose levels are when my sleep is crappy.” The correlation between high glucose levels (by proxy high cortisol) and crappy sleep.",
  "content_length": 483,
  "content_tokens": 115,
  "embedding": []
 },
 {
  "title": "Dexcom and Competitors",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom vs. the competitors, the less invasive options, and the fundamental problems needing to be solved with CGM technologies. How does Dexcom perform compared to its competitors? Dexcom has studies that they’’ve published comparing Dexcom CGM to other ⇒ “We maintain our performance all the time.” Peter has been vocal about this, “it’s not a subtle difference.” “We perform extremely well across all the range of glucose in the low and in the high range.” One of Dexcom’s goals is to have a smaller sensor with a shorter needle. Currently, the needle goes down to the interstitial fluid, but they are testing ones that go even shallower. But there are complications of a shorter sensor (What do the membrane layers look like so you can get an extended wear on a 14-day sensor? How’s electrochemical reaction on a longer life sensor if it’s shorter versus the one that we have now?). A lot of trial and error while trying to determine what is the best combination of all of these features. “I think we’ll have a shorter one. Right now, we’re very comfortable with the interstitial fluid.” ⇒ Peter’s take on the pain related to the insertion of the sensor: “Once it’s in there, I don’t actually know the difference between it being in me versus on the skin.” Why can’t this be done optically (i.e. without going into the skin)? Or with a “pulse oximeter where you put it on your finger”? It has been tried on numerous occasions.",
  "content_length": 1429,
  "content_tokens": 357,
  "embedding": []
 },
 {
  "title": "The fundamental problems needing to be solved with these CGM technologies",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The fundamental problems needing to be solved with these CGM technologies are accuracy, conveniency, the cost, and can they produce a health care outcome.",
  "content_length": 154,
  "content_tokens": 30,
  "embedding": []
 },
 {
  "title": "The cost of CGM, why you need a prescription, and when might there be a OTC option?",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The cost of the CGM is the biggest barrier to getting more users. Additionally, you need a prescription, and unless you have diabetes, you will be paying out of pocket for it. Typically our patients pay 20% of the cost (standard co-pay for durable medical equipment). Sensors come in boxes of 3. Peter’s practice typically buys them 9 at a time (about a 3 month supply) for patients. And they pay about $9-$11 per day.",
  "content_length": 418,
  "content_tokens": 98,
  "embedding": []
 },
 {
  "title": "Why can’t the CGM be a nonprescription product?",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter points out that Dexcom as a business is basically doing incredibly well serving just a tiny fraction of people (T1D and some T2D). But another 10% of the population is pre-diabetic. And then another huge chunk of people are focused on “wellness” and longevity and would benefit from better glycemic control. There’s a lot of steps we’d have to go through at the FDA. A nonprescription device would need to have a different software experience. Currently it is a class 2 medical device.",
  "content_length": 491,
  "content_tokens": 114,
  "embedding": []
 },
 {
  "title": "The role of the FDA",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Must go through clinical trials particularly if labeled for use for people with diabetes to demonstrate the accuracy and consistency of the product across all glucose ranges. The FDA in all candor on has been very progressive with Dexcom. First company ever to go directly to the phone. We’re the first company to share data. We’re the first company ever to have a sensor perform the accuracy levels that we have. In fact, most every “first” with the FDA in our industry has come through companies that are partnering with Dexcom.",
  "content_length": 530,
  "content_tokens": 111,
  "embedding": []
 },
 {
  "title": "FDA's new category for continuous glucose monitoring",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The FDA recently created a new category for continuous glucose monitoring.",
  "content_length": 74,
  "content_tokens": 12,
  "embedding": []
 },
 {
  "title": "Over-the-counter CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In the future, Dexcom would love to have a OTC device to sell through nutrition programs but that a patient could NOT use to dose insulin. Why does the FDA say an OTC product cannot be used to dose insulin? Maybe that will change over time, but for now those are the rules that Dexcom has to play by.",
  "content_length": 300,
  "content_tokens": 68,
  "embedding": []
 },
 {
  "title": "When and what needs to happen for an OTC product?",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin is hopeful that this will happen. Dexcom would have to present again is a case as to how somebody would never harm themselves. The fact that there is a needle that needs to be inserted complicates this issues ⇒ There may be standards and rules around needles. So I can’t speculate how we’d get there, but I think over time that’s something we would like to take on.",
  "content_length": 371,
  "content_tokens": 86,
  "embedding": []
 },
 {
  "title": "Smartwatch integration, bluetooth technology, and exciting collaborations and partnerships",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom is currently working on a “direct to watch” transmitter to send data directly from sensor to the Apple Watch (and other smart watches such as Android). The watch would then become a patient’s receiver and the data could still be shared without having to go through your phone. G6 can store data and then back load it once it gets within range of your phone. Exciting collaborations and partnerships with Apple, Verily/Onduo, and United Healthcare.",
  "content_length": 454,
  "content_tokens": 98,
  "embedding": []
 },
 {
  "title": "Future places for CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter asks: Why isn’t the Dexcom CGM in the ICU of all places? “We tried.”",
  "content_length": 74,
  "content_tokens": 28,
  "embedding": []
 },
 {
  "title": "G6 in the hospital",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The G6 can monitor patients (especially diabetics) and dosing insulin. Nurses can connect the Bluetooth to the nurses station so they can see glucose in real time. Currently, nurses may have to finger stick a patient every 30 minutes (48 finger sticks in a 24-hour period).",
  "content_length": 273,
  "content_tokens": 60,
  "embedding": []
 },
 {
  "title": "Acetaminophen and G6",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Taking acetaminophen (Tylenol) does not affect the accuracy/performance of the G6 (it affected previous models). Dexcom ran a very large study and put a lot of acetaminophen into patients with no performance problems.",
  "content_length": 217,
  "content_tokens": 49,
  "embedding": []
 },
 {
  "title": "Challenges with CGM in ICU patients",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "ICU patients are typically on a bunch of drugs. Also, they “third space” like crazy so their interstitial looks totally different from a normal person’s.",
  "content_length": 153,
  "content_tokens": 37,
  "embedding": []
 },
 {
  "title": "CGM for gestational diabetes",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The CGM is not yet approved for gestational diabetes. A study in gestational diabetes is needed to get that label. Dexcom wants to run studies to see if the CGM can be used as a diagnostic tool for gestational diabetes.",
  "content_length": 219,
  "content_tokens": 49,
  "embedding": []
 },
 {
  "title": "CGM and nutrition apps",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom would like to combine CGM with some of the nutrition apps. For example, the Weight Watchers app. If that had glucose data and you ate your 32 points today but your glucose factor was still high, maybe we take you down to 26. CGM can integrate wonderfully (without showing a glucose value that you dose insulin off of).",
  "content_length": 325,
  "content_tokens": 70,
  "embedding": []
 },
 {
  "title": "Glucose values vs weight loss",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter thinks glucose values are a much better metric for health than weight loss. Weight is correlated with health, but the correlation is not exceptional. It’s reasonable, but it’s so far from great. And my prediction would be when those trials are done, your average blood glucose, your standard deviation of blood glucose over a three month period is going to tell you infinitely more than whatever the fluctuations were in your weight.",
  "content_length": 439,
  "content_tokens": 87,
  "embedding": []
 },
 {
  "title": "Type of weight matters more than total weight loss",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Subcutaneous fat not as “bad” as visceral fat. Also, where that fat resides on somebody probably tells us much more about their metabolic health.",
  "content_length": 145,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "Lessons you learn from wearing a CGM",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "What you learn is going to alter your behavior. You learn other really interesting things: How much even exercise can transiently raise your blood glucose, but what the benefits are after the fact (which is your ability to dispose of glucose goes up significantly).",
  "content_length": 265,
  "content_tokens": 50,
  "embedding": []
 },
 {
  "title": "Dexcom’s unique company culture",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom is a fairly big public company.",
  "content_length": 38,
  "content_tokens": 9,
  "embedding": []
 },
 {
  "title": "Blending startup mentality with structure of a big company",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom is trying to mix the nimbleness of a startup with the big company structure where they have systems and balances and checks to make sure they are doing the right thing and watching dollars more.",
  "content_length": 201,
  "content_tokens": 41,
  "embedding": []
 },
 {
  "title": "Dexcom's employees",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Dexcom has several people with Type 1 diabetes that work there because they can lend perspective for their patients that they don’t have on their own. They learn a lot through in-house studies and through that in-house wear process.",
  "content_length": 232,
  "content_tokens": 49,
  "embedding": []
 },
 {
  "title": "Lessons learned through failures and success",
  "date": "May 20, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Kevin learned to be better prepared in how he delivers his message after presenting his point of view and being rejected twice. He also learned that sometimes the biggest blessings are the little failures along the way and to surround himself with great people.",
  "content_length": 261,
  "content_tokens": 46,
  "embedding": []
 }
]